Huacapurana — Hermetica Encyclopedia
Herb · Amazonian

Huacapurana (Campsiandra comosa)

Preliminary EvidenceCompound

Hermetica Superfood Encyclopedia

The Short Answer

Huacapurana bark contains flavonoids, condensed tannins (proanthocyanidins), and triterpenoids including β-sitosterol and lupeol, which collectively scavenge free radicals via DPPH and Fe³⁺ reduction pathways and modulate inflammatory signaling. Preclinical in vitro evidence demonstrates antioxidant, antiangiogenic, and antibacterial activity against Pseudomonas fluorescens, though no human clinical trials have been completed to quantify effect sizes or establish therapeutic doses.

PubMed Studies
7
Validated Benefits
Synergy Pairings
At a Glance
CategoryHerb
GroupAmazonian
Evidence LevelPreliminary
Primary Keywordhuacapurana benefits
Huacapurana close-up macro showing natural texture and detail — rich in antioxidant, anti-inflammatory, stress
Huacapurana — botanical close-up

Health Benefits

**Antioxidant Activity**
Methanol bark extracts exhibit the strongest free radical scavenging capacity among all tested plant fractions, attributed to flavonoid and phenolic content measurable via DPPH and ferric-reducing (Fe³⁺/phenanthroline) assays; bark fractions consistently outperform leaf and branch preparations.
**Anti-inflammatory Potential**
Proanthocyanidins and flavonoids present in the bark of Campsiandra species are structurally analogous to compounds known to inhibit cyclooxygenase (COX) pathways and reduce pro-inflammatory cytokine expression, providing a pharmacognostic rationale for traditional use in febrile and inflammatory conditions.
**Antiangiogenic Effects**
Extracts from leaves and bark (excluding hexane fractions) demonstrated antiangiogenic activity in the chick chorioallantoic membrane (CAM) assay, suggesting potential relevance to conditions involving pathological neovascularization, possibly mediated by flavonoid modulation of VEGF signaling.
**Antibacterial Properties**
Campsiandra comosa extracts show inhibitory activity against Pseudomonas fluorescens in preliminary screening, and related species exhibit broader antibacterial and antifungal activity, consistent with the tannin-rich phytochemical profile that disrupts microbial membrane integrity.
**Gastrointestinal Support**
Ethnopharmacological records and studies on the related species Campsiandra laurifolia link tannin- and saponin-rich aqueous bark extracts to protection against mucosal oxidative stress in colitis models, supporting traditional use of Huacapurana preparations for gut health and ulcer management.
**Immune Modulation**
Traditional Amazonian curanderos employ Huacapurana bark decoctions for immune support during malarial fever episodes; the combination of flavonoids and triterpenoids (β-sitosterol, lupeol) provides a phytochemical basis for immune-regulatory activity, though mechanistic studies in immune cell lines are absent.
**Low Cytotoxicity Profile**
All tested extracts (leaves, bark, branches across methanol and hexane solvents) proved non-toxic in the Artemia salina brine shrimp lethality assay at concentrations from 62.5 to 1000 µg/mL, correlating high flavonoid content with cellular safety and supporting a favorable therapeutic index at preclinical concentrations.

Origin & History

Huacapurana growing in Amazon — natural habitat
Natural habitat

Campsiandra comosa is a leguminous tree (family Fabaceae) native to the Amazon basin, distributed across Peru, Brazil, and neighboring South American countries, thriving in flooded várzea forests, riparian zones, and humid lowland tropical environments. The tree is wild-harvested rather than cultivated, with documented collection sites including the Lake Catalão region of Brazil and the Iquitos corridor of Peruvian Amazonia. Bark is the primary harvested material, stripped from mature trunks and used fresh or dried by local herbalists and curanderos.

Huacapurana has been used for generations by indigenous Amazonian peoples and mestizo herbalists (curanderos) in the Peruvian Amazon, particularly in the Iquitos region, primarily as a treatment for malarial fever, inflammatory conditions, intestinal disorders, and general immune debility. The name 'Huacapurana' is applied variably across multiple Campsiandra species (C. comosa, C. angustifolia) and occasionally to other Amazonian timber trees, reflecting the fluid ethnobotanical nomenclature of Amazonian folk medicine where efficacy is attributed to the bark preparation rather than to a strictly defined botanical taxon. Bark decoctions and alcohol-macerated preparations are the canonical forms referenced in ethnopharmacological surveys of Peruvian and Brazilian Amazonia, with the bark's astringent quality—attributable to its tannin content—recognized empirically by practitioners as a marker of medicinal potency. The species C. laurifolia, a congener used similarly for gastric ulcer management in other Amazonian communities, reinforces the genus-wide ethnomedical tradition of using Campsiandra bark for mucosal and inflammatory conditions.Traditional Medicine

Scientific Research

The published evidence base for Campsiandra comosa is limited to a small number of phytochemical screening and in vitro bioactivity studies, with no peer-reviewed human clinical trials identified as of 2024. Primary research includes DPPH radical scavenging and Fe³⁺ reduction assays confirming antioxidant activity in methanol extracts, antibacterial disk diffusion against P. fluorescens, antiangiogenic testing on chick chorioallantoic membrane, and Artemia salina cytotoxicity assays—all in vitro or ex ovo models with no sample sizes reported in accessible summaries. A study on the related species C. laurifolia used an acetic acid-induced colitis rat model to evaluate aqueous hull extract for antioxidant effects, providing the only in vivo mammalian data within the genus, but published details on group sizes, statistical power, and effect magnitudes were not available in accessible literature. Compound isolation was confirmed via NMR and thin-layer chromatography (TLC with FeCl₃ staining), yielding β-sitosterol, lupeol, and one uncharacterized compound, but no quantitative concentration data (mg/g dry weight) were reported for any bioactive constituent.

Preparation & Dosage

Huacapurana prepared as liquid extract — pairs with Huacapurana bark is traditionally combined with other Amazonian anti-inflammatory botanicals such as Cat's Claw (Uncaria tomentosa) in Peruvian herbal formulations; both contain proanthocyanidins and oxindole alkaloids that may complement NF-κB suppression and COX inhibition through parallel but distinct pathways, though no pharmacokinetic interaction studies confirm additive or synergistic effects. The β-sitosterol content
Traditional preparation
**Alcohol Tincture (Commercial)**
5 ml (approximately 30 drops) per day in water or juice, though this dosage lacks clinical trial validation
Campsiandra angustifolia bark tincture at 1:3 dry herb potency; commercially recommended dose is 1..
**Bark Decoction (Traditional)**
Bark pieces boiled in water for 20–40 minutes; volume and frequency are unspecified in scientific literature and vary by Amazonian practitioner tradition.
**Methanol/Ethanol Extract (Research Grade)**
Used in laboratory studies at concentrations of 62.5–1000 µg/mL; not directly applicable to consumer supplementation without pharmacokinetic bridging studies.
**Standardization**
No standardized extract exists specifying a minimum percentage of flavonoids, proanthocyanidins, or tannins; current commercial products are not standardized to any confirmed active marker.
**Timing and Duration**
No evidence-based guidance on administration timing or maximum treatment duration; traditional use is episodic (e.g., during fever or gut distress) rather than chronic daily supplementation.
**Forms Available**
Dried bark (bulk herb), alcohol tinctures, and aqueous bark extracts are the primary forms; capsule or tablet formulations are not widely documented in either research or commerce.

Nutritional Profile

Huacapurana bark is not consumed as a food source and therefore lacks a conventional macronutrient profile; its nutritional relevance is entirely phytochemical. Confirmed phytochemical classes in C. comosa bark methanol extracts include flavonoids (unquantified total), condensed tannins/proanthocyanidins (unquantified), phenolic compounds (detected via FeCl₃ TLC staining), triterpenoids β-sitosterol and lupeol (isolated in milligram quantities from research fractionations, Rf values 0.9–1.0 and 0.5 respectively), and a third uncharacterized compound (8 mg isolated, Rf 0.5). No mineral content, vitamin profile, or caloric data are reported for bark preparations. Bioavailability of bark-derived flavonoids and proanthocyanidins is expected to be moderate and highly dependent on preparation method, as aqueous decoctions favor polar phenolic extraction while alcohol tinctures enhance recovery of less polar flavonoids and triterpenoids; no pharmacokinetic absorption, distribution, metabolism, or excretion (ADME) studies exist for C. comosa constituents.

How It Works

Mechanism of Action

Flavonoids and condensed tannins (proanthocyanidins) in Huacapurana bark function as electron donors that directly quench reactive oxygen species (ROS), reducing Fe³⁺ to Fe²⁺ and neutralizing DPPH radicals through phenolic hydroxyl group donation, thereby lowering cellular oxidative burden. The triterpenoid β-sitosterol competitively inhibits cholesterol absorption at intestinal brush borders and has demonstrated NF-κB pathway suppression in analogous species, while lupeol—also isolated from C. comosa methanol fractions—inhibits 5-lipoxygenase and COX-2 activity in preclinical models, attenuating leukotriene and prostaglandin synthesis. Antiangiogenic activity observed in the CAM assay is hypothesized to involve flavonoid-mediated downregulation of vascular endothelial growth factor (VEGF) receptor signaling, though the precise molecular targets within the MAPK/ERK or PI3K/Akt cascades have not been characterized for C. comosa specifically. Antibacterial effects against Pseudomonas fluorescens are consistent with tannin-mediated disruption of bacterial outer membrane integrity and inhibition of membrane-associated enzymes, a mechanism well-documented for proanthocyanidin-rich plant extracts.

Clinical Evidence

No clinical trials in human subjects have been conducted on Campsiandra comosa or on Huacapurana preparations more broadly, meaning all efficacy inferences are extrapolated from in vitro assays, one rodent colitis model (C. laurifolia), and extensive traditional use documentation. The in vitro antioxidant, antiangiogenic, and antibacterial findings are consistent in direction but lack quantified IC₅₀ values or dose-response curves in most available reports, limiting translation to human dosing. Commercial products referencing anti-inflammatory efficacy comparable to NSAIDs represent marketing claims unsupported by any controlled comparison trial. Until randomized controlled trials are performed, confidence in specific therapeutic outcomes remains very low, and clinical recommendations cannot be derived from existing data.

Safety & Interactions

Campsiandra comosa extracts demonstrated no toxicity against Artemia salina brine shrimp at concentrations up to 1000 µg/mL across all solvent fractions (methanol and hexane, from leaves, bark, and branches), representing a favorable preliminary cytotoxicity signal, but this assay has limited predictive value for chronic human toxicity or organ-specific effects. No human adverse event data, maximum tolerated dose, or formal toxicology studies (Ames test, subacute/chronic rodent toxicity, hepatotoxicity panels) have been published for any Campsiandra species, making long-term safety in humans entirely undetermined. Drug interaction risk is theoretically present given the tannin content—high-tannin preparations can reduce oral absorption of iron, certain antibiotics (tetracyclines, fluoroquinolones), and alkaloid-based medications by forming insoluble complexes—and the β-sitosterol content may additively lower LDL cholesterol in patients on statins. Use during pregnancy and lactation is not supported by any safety data and should be avoided; individuals with known tannin sensitivity, gastrointestinal strictures, or those taking iron supplementation or anticoagulant therapy should consult a healthcare provider before use.

Synergy Stack

Hermetica Formulation Heuristic

Also Known As

VacapuranaHuacapurana (Campsiandra angustifolia)Campsiandra comosaPalo de HuacapuranaCampsiandra angustifoliaHuacapurana bark

Frequently Asked Questions

What is huacapurana used for traditionally?
Huacapurana bark has been used by Peruvian Amazonian indigenous peoples and curanderos primarily for malarial fever, general inflammation, gut health disorders including ulcers, and immune support during illness. Preparations typically involve boiling the bark into a decoction or macerating it in alcohol, with the bark's notable astringency—caused by its tannin content—recognized empirically as a sign of medicinal activity. These uses are documented through ethnopharmacological surveys rather than clinical trials.
What are the active compounds in huacapurana bark?
Campsiandra comosa bark methanol extracts contain flavonoids, condensed tannins (proanthocyanidins), phenolic compounds, and triterpenoids including β-sitosterol and lupeol, all confirmed by NMR spectroscopy and thin-layer chromatography. β-sitosterol and lupeol have established anti-inflammatory and antioxidant activity in other botanical contexts, providing a plausible pharmacognostic basis for traditional use. No precise concentration data (mg per gram of dried bark) have been published for any of these constituents.
Is there clinical trial evidence for huacapurana?
No human clinical trials have been completed or published for Campsiandra comosa or any Huacapurana preparation as of 2024. Available evidence is restricted to in vitro assays (DPPH antioxidant, antibacterial disk diffusion, chick embryo antiangiogenic CAM assay) and one rodent colitis model using the related species C. laurifolia. Claims comparing huacapurana efficacy to NSAIDs are not substantiated by any controlled trial data.
What is the recommended dosage for huacapurana tincture?
Commercial huacapurana tinctures based on Campsiandra angustifolia bark (prepared at a 1:3 dry herb-to-solvent ratio) are typically labeled at 1.5 ml (approximately 30 drops) per day, taken in water or juice. This dosage is derived from traditional herbalist practice and commercial convention, not from pharmacokinetic or dose-finding clinical studies. No standardized extract specifying minimum active compound percentages exists, so potency across products varies considerably.
Is huacapurana safe to take daily?
Preliminary safety data from Artemia salina brine shrimp assays show no cytotoxicity for C. comosa extracts at concentrations up to 1000 µg/mL, suggesting low acute cellular toxicity at tested levels. However, no chronic toxicity studies, human adverse event reports, or formal drug interaction investigations have been published, meaning long-term daily safety in humans is genuinely unknown. Individuals taking oral iron supplements, tetracycline antibiotics, or anticoagulants should exercise caution due to the tannin content, which can reduce absorption of these substances.
Which part of huacapurana has the strongest antioxidant activity?
The bark of huacapurana demonstrates the strongest free radical scavenging capacity compared to leaf and branch preparations, as measured by DPPH and ferric-reducing assays. This superior antioxidant activity in the bark is attributed to its higher concentration of flavonoids and phenolic compounds. Bark-based extracts and tinctures are therefore the most potent form for obtaining antioxidant benefits from this plant.
Does huacapurana interact with anti-inflammatory medications?
Huacapurana contains proanthocyanidins and flavonoids with documented anti-inflammatory potential, which theoretically could potentiate the effects of pharmaceutical anti-inflammatory drugs. While the plant's traditional use suggests safety, combining huacapurana supplements with prescription anti-inflammatory medications (NSAIDs, corticosteroids) warrants consultation with a healthcare provider to avoid additive effects. No specific drug interaction studies have been conducted on huacapurana with common medications.
How does huacapurana compare to other rainforest herbs for antioxidant strength?
Huacapurana bark exhibits particularly robust antioxidant activity in standardized laboratory assays (DPPH and ferric-reducing tests), positioning it among potent botanical antioxidants. The strength of its antioxidant capacity stems specifically from measurable flavonoid and phenolic content, making it comparable to other polyphenol-rich rainforest botanicals. Direct comparative studies between huacapurana and other Amazonian herbs are limited, but its performance in free radical scavenging assays suggests competitive antioxidant potential.

Explore the Full Encyclopedia

7,400+ ingredients researched, verified, and formulated for optimal synergy.

Browse Ingredients
These statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.